| Literature DB >> 20815897 |
Khedidja Mekki1, Warda Taleb, Nassima Bouzidi, Abbou Kaddous, Malika Bouchenak.
Abstract
OBJECTIVE: To investigate the effects of hemodialysis (HD) and periotoneal dialysis (PD) on oxidative stress in chronic renal failure patients (CRF).Entities:
Mesh:
Substances:
Year: 2010 PMID: 20815897 PMCID: PMC2941489 DOI: 10.1186/1476-511X-9-93
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Clinical and biochemical characteristics of the patients
| CRF | HD | PD | |
|---|---|---|---|
| Patients | N = 20 | N = 20 | N = 20 |
| Age (years) | 61 ± 13 | 36 ± 12 | 40 ± 8 |
| Weight (kg) | 71.5 ± 8.07 | 56.71 ± 13.87 | 65.87 ± 18.22 |
| BMI (Kg/m2) | 27 ± 3 | 21 ± 4 | 23 ± 5 |
| Sex ratio (M/F) | 4/16 | 8/12 | 10/10 |
| Dialysis duration (months) | - | 12 - 60 | 3 - 48 |
| Glucose (g. L-1) | 0.90 ± 0.06 | 0.85 ± 0.02 | 0.95 ± 0.06 |
| Creatinin (μmol.ml-1) | 221 ± 94 | 834 ± 47 | 735 ± 194 |
| Urea (mmol.L-1) | 12 ± 4 | 14 ± 1 | 12 ± 0.8 |
| Total proteins (g. L-1) | 66 ± 0.6 | 60 ± 1.2 | 57 ± 0.9 |
Data are expressed in mean ± SD. BMI: Body mass index (weight kg/height m2). SBP: Systolic blood pressure, DBP: Diastolic blood pressure.
Lipids, apolipoproteins and atherogenic indices of the study groups
| CRF | HD | PD | |
|---|---|---|---|
| TG (mmol.L-1) | 3.11 ± 0.4 | 1.48 ± 0.62** | 1.7 ± 0.42** |
| TC (mmol.L-1) | 6.02 ± 2.48 | 6.82 ± 1.29 | 4.7 ± 1.57 # |
| HDL-C (mmol.L-1) | 1.29 ± 0.94 | 1.09 ± 0.41 | 1.07 ± 0.53 |
| LDL-C (mmol.L-1) | 2.25 ± 0.62 | 3.76 ± 0.27**# | 2.35 ± 0.40 |
| Apo A-I (g. L-1) | 1.07 ± 0.53 | 1.11 ± 0.14 | 0.89 ± 0.48 |
| Apo B (g. L-1) | 0.34 ± 0.05 | 0.27 ± 0.07 | 0.30 ± 0.04 |
| TC/HDL-C | 7.38 ± 0.34 | 4.88 ± 0.73 * | 2.27 ± 0.48**### |
| LDL-C/HDL-C | 2.50 ± 0.94 | 2.96 ± 0.35 | 2.59 ± 1.36 |
| Apo AI/Apo B | 2.43 ± 0.85 | 3.89 ± 0.67 | 3.04 ± 1.75 |
CRF: End stage chronic renal failure patients. HD: patients on hemodialysis. PD: Patients on peritoneal dialysis. Data are presented as the mean ± SD. HD group and PD group vs CRF group # HD group vs PD group. *# (P < 0.05); **##(P < 0.01); ###(P < 0.001)
Oxidative status in the study groups
| CRF | HD | PD | |
|---|---|---|---|
| TBARS (μmol.L-1) | 0.12 ± 0.01 | 0.23 ± 0.02* | 0.18 ± 0.01* |
| TBARS-VLDL (μmol.L-1) | 0.55 ± 0.02 | 0.10 ± 0.05** | 0.026 ± 0.014** |
| TBARS-LDL (μmol.mL1) | 0.038 ± 0.002 | 0.055 ± 0.023* | 0.052 ± 0.014* |
| TBARS-HDL2 (μmol.mL1) | 0.09 ± 0.01 | 0.047 ± 0.008* | 0.023 ± 0.01*# |
| TBARS-HDL3 (μmol.mL1) | 0.196 ± 0.05 | 0.105 ± 0.070 | 0.231 ± 0.049 |
| Carbonyls (μmol.mL1) | 0.3 ± 0.16 | 0.92 ± 0.15* | 1.90 ± 0.10**## |
CRF: End stage chronic renal failure patients. HD: patients on hemodialysis. PD: Patients on peritoneal dialysis. Data are presented as the mean ± SD. * HD group and PD group vs CRF group # HD group vs PD group. *#(P < 0.05); **##(P < 0.01)
Antioxidative status in the study groups
| CRF | HD | PD | |
|---|---|---|---|
| SOD (U.ml-1) | 82.10 ± 1.53 | 70.08 ± 4.20* | 80.12 ± 0.38# |
| GSH-Px (U.ml-1) | 5.92 ± 0.53 | 4.12 ± 0.3* | 4.08 ± 0.06* |
| Catalase (U.ml-1) | 85.45 ± 4.74 | 80.18 ± 1.32 | 65.78 ± 3.45**# |
| Nitric oxide (μmol.L-1) | 22.53 ± 7.24 | 30.57 ± 8.7* | 20.52 ± 1.58 |
| Albumins (g.L-1) | 32.95 ± 0.25 | 30.78 ± 1.18* | 29.50 ± 0.07* |
| Urate (μmol/L) | 513.94 ± 171.61 | 382.09 ± 66.07*** | 349.63 ± 167.2*** |
| Bilirubin (μmol/L) | 6.29 ± 2.60 | 5.01 ± 0.60 | 8.39 ± 6.76 |
| Iron (μmol/L) | 33.08 ± 7.71 | 55.17 ± 1.53 *** | 40.59 ± 3.07### |
| CRP (mg L-1) | 6.5 ± 0.2 | 8.2 ± 0.2* | 8.8 ± 0.8* |
CRF: End stage chronic renal failure patients. HD: patients on hemodialysis. PD: Patients on peritoneal dialysis. Data are presented as the mean ± SD. * HD group and PD group vs CRF group # HD group vs PD group. *# (P < 0.05); **(P < 0.01); ***###(P < 0.001)